Thursday's Health Winners & Losers

Stock quotes in this article: CORT , VVUS , ADLS , IDMI , CBTE , TTG , VRX  

Updated from 2:25 p.m. EDT

Study updates launched and sank a few biotech stocks Thursday while the overall mood was grim.

Corcept Therapeutics(CORT Quote) closed up 23.2% after saying preliminary top-line results showed a statistically significant reduction in weight gain in patients who took olanzapine plus corlux compared to those who took olanzapine alone in a two-week, male-only, proof-of-concept study. The announcement managed to pump the stock 33 cents to $1.75.

Pharmaceutical company Vivus(VVUS Quote) said it finished a meeting with the Food and Drug Administration, following the completion of its phase II program for investigative obesity treatment Qnexa. As a result of the meeting, the company said it will dose 4,500 patients in a pivotal 56-week phase III program studying obese patients and obese patients with associated comorbidities, or conditions that exist in addition to obesity such as type 2 diabetes, hypertension and dislipidemia.

It intends to initiate enrollment this fall and is preparing an application for special protocol assessment for the drug as a treatment for obesity in the U.S. After rising 16 cents to $5.17 in premarket trading, the company was hugging the flat line, down 5 cents to $4.96.

Vivus is part of the Nasdaq biotechnology index, which was up less than 1 point at 812.61.

  • Loading Comments...
  •  
< Previous
1 2 3

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin

Recent Comments





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,404.85 1,102.88 2,196.79 34.87
Oil *
71.46
UP
67.80
UP
6.94
UP
13.06
UP
0.64
10 Yr
3.49%
SPDR Gold
110.29
+0.66%
+0.63%
+0.60%
+1.87%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services